1. Home
  2. OI vs MESO Comparison

OI vs MESO Comparison

Compare OI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

HOLD

Current Price

$15.43

Market Cap

2.0B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$18.22

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OI
MESO
Founded
1903
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OI
MESO
Price
$15.43
$18.22
Analyst Decision
Buy
Strong Buy
Analyst Count
7
2
Target Price
$16.29
$24.00
AVG Volume (30 Days)
2.3M
206.1K
Earning Date
11-04-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,455,000,000.00
$17,198,000.00
Revenue This Year
$1.41
$465.44
Revenue Next Year
$1.99
$75.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
191.39
52 Week Low
$9.23
$9.61
52 Week High
$16.04
$22.00

Technical Indicators

Market Signals
Indicator
OI
MESO
Relative Strength Index (RSI) 73.59 60.70
Support Level $13.01 $16.43
Resistance Level $14.60 $17.65
Average True Range (ATR) 0.49 0.61
MACD 0.17 0.25
Stochastic Oscillator 99.46 73.73

Price Performance

Historical Comparison
OI
MESO

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: